| 2003/8/159 | BOCS (Formely FBCS) | 31/12/2020 |
| 2001-11-162 | TEAM | 01/01/2019 |
| 1903782 | A phase 2 study of LAG525 with PDR001 and carboplatin in advanced TNBC | 07/02/2021 |
| 1902773 | DANTE (Duration of Anti-PD1 therapy for melanoma) | 28/02/2023 |
| 1902765 | Ribociclib Non-Interventional Study | 15/08/2022 |
| 1901755 | Ferring 000108 PRONOUNCE | 15/04/2022 |
| 1901749 | CALLS – CML and ALL Low Level Mutation Study | 31/12/2018 |
| 1901747 | MUK nine b: OPTIMUM | 31/12/2021 |
| 1901746 | MUK nine a: screening study | 15/01/2024 |
| 1812732 | Daiichi Sankyo DS8201-A-U201 (DS-8201a) | 30/04/2019 |
| 1812731 | B-AHEAD3: Breast Activity and Healthy Eating After Diagnosis 3 | 28/02/2020 |
| 1810700 | PLATO – PersonaLising Anal cancer radioTherapy dOse | 31/01/2022 |
| 1810695 | OPINION, Olaparib Maintenance Monotherapy Ovarian Cancer. | 30/09/2020 |
| 1805632 | National Lung Matrix: Multi-Drug Phase II trial in NSC Lung Cancer | 01/10/2021 |
| 1805629 | ROVA-T Maintenance in SCLC (MERU) | 30/04/2020 |
| 1805626 | LCH-IV | 01/12/2025 |
| 1804571 | Open Label Study of Relugolix in Men with Advanced Prostate Cancer | 30/11/2019 |
| 1803566 | CTC-STOP | 31/01/2021 |
| 1802579 | PRAN-16-52 Pracinostat in combination with Azacitidine in Adult AML | 30/12/2019 |
| 1802571 | CR UK Stratified Medicine Pilot study | 31/12/2020 |
| 1712545 | CITADEL-202: Safety and Efficacy of INCB050465 in B-Cell Lymphoma | 01/06/2020 |
| 1712541 | Gilteritinib as Maintenance After Induction/Consolidation in CR1 AML (Astellas AML Maintenance Study | 14/03/2019 |
| 1712540 | CHRONOS-4 | 25/02/2025 |
| 1710507 | Niraparib in men with mCRPC and DNA repair anomalies | 30/06/2020 |
| 1708490 | PRIMETIME | 24/01/2021 |
| 1708470 | plasmaMATCH | 31/05/2019 |
| 1707467 | CompLEEment-1 | 09/11/2020 |
| 1706435 | Myeloma XII (ACCoRd trial) Version 1.0 | 31/01/2026 |
| 1706433 | MUK8 | 31/12/2018 |
| 1704408 | DETECT I | 01/02/2019 |
| 1704403 | TREATT: Trial to EvaluAte Tranexamic acid therapy in Thrombocytopenia | 31/08/2019 |
| 1703398 | CANC – 4658 | 18/09/2021 |
| 1703394 | IMRiS | 30/09/2020 |
| 1703390 | CONCEPT: A Phase II pilot study of 3 weekly Cabazitaxel versus weekly Paclitaxel chemotherapy in the first line treatment of Her2 negative metastatic breast cancer (mBC) | 31/12/2020 |
| 1702383 | CANC 5507 | 14/06/2019 |
| 1702380 | CANC 5081 | 30/08/2019 |
| 1702374 | Prepare-ABC | 01/05/2020 |
| 1612350 | INCA | 30/04/2021 |
| 1610318 | AML19 | 09/11/2031 |
| 1610314 | HART | 31/01/2023 |
| 1608296 | Hartmann’s procedure versus intersphincteric APE: a prospective study | 30/06/2019 |
| 1607275 | DARS | 01/06/2020 |
| 1605234 | EMBARK:MDV3100-13 Phase3, Enzalutamide, nonmetastatic Prostate Cancer | 30/11/2020 |
| 1604237 | SelPac | 31/12/2018 |
| 1604233 | CANC – 4039 – Pharmacokinetics of Ramucirumab in Second Line Gastric Adenocarcinoma (JVDB) | 01/05/2022 |
| 1603225 | ACELARATE | 31/12/2020 |
| 1603223 | CANC – 4556 | 31/03/2019 |
| 1602212 | CompARE Trial | 01/11/2020 |
| 1601206 | MelMarT | 31/12/2026 |
| 1601198 | Add-Aspirin Trial | 15/08/2030 |
| 1512190 | NCRN – 3312 – MPDL3280A vs Chemotherapy in Urothelial Bladder Cancer | 15/06/2021 |
| 1508136 | MCL Biobank Observational Study | 30/10/2019 |
| 1507112 | STAR Standard vs Modified Drug Therapy in Renal Cancer | 20/02/2019 |
| 1503071 | FLAIR | 30/01/2020 |
| 1502056 | The Molecular Investigation of Unexplained Anaemias | 30/11/2023 |
| 1411013 | FOCUS 4 | 01/04/2020 |
| 1408976 | DESTINY | 20/09/2019 |
| 1407965 | De-ESCALaTE HPV | 01/01/2022 |
| 1406946 | NCRN – 2639 / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC | 23/01/2024 |
| 1312865 | NCRN487 ECHELON-1: A+AVD vs ABVD in first line advanced Hodgkin Lymphoma | 11/04/2020 |
| 1311856 | RAPPER | 31/03/2022 |
| 1309829 | BRF115532 | 01/01/2030 |
| 1305779 | IoN | 01/02/2019 |
| 1301726 | UKALL 2011 | 30/04/2019 |
| 1210712 | INTERLACE | 01/12/2019 |
| 1210711 | ESPAC-4 | 31/12/2018 |
| 1207674 | SEARCH | 30/09/2019 |
| 1206664 | FAST-Forward | 31/08/2028 |
| 1204623 | Aristotle | 29/06/2019 |
| 1008419 | Expression of tumour specific proteins during metastasis | 31/08/2020 |
| 1002346 | IMPACT | 31/12/2018 |
| 907288 | RADICALS (MRC PR10) | 01/05/2020 |
| 902246 | MDSBio | 24/06/2021 |
| 810202 | AVAST-M | 01/03/2022 |
| 809194 | ALTTO – Adjuvant Lapatinib and/or Trastuzumab | 01/02/2021 |
